يعرض 1 - 20 نتائج من 185 نتيجة بحث عن '"Garin, M"', وقت الاستعلام: 0.60s تنقيح النتائج
  1. 1
  2. 2
    Report
  3. 3
    Report
  4. 4
    Academic Journal
  5. 5
    Academic Journal
  6. 6
    Report
  7. 7
    Conference
  8. 8
    Conference
  9. 9
    Academic Journal

    المساهمون: Ministerio de Ciencia, Innovación y Universidades, Spanish National Plan for Scientific and Technical Research and Innovation, European Regional Development Fund

    المصدر: Small ; volume 19, issue 39 ; ISSN 1613-6810 1613-6829

  10. 10
    Academic Journal

    المساهمون: Spanish Ministry of Science and Innovation, University of the Basque Country

    المصدر: International Journal of Production Research ; volume 62, issue 4, page 1262-1276 ; ISSN 0020-7543 1366-588X

  11. 11
    Academic Journal
  12. 12
    Academic Journal
  13. 13
    Academic Journal
  14. 14
    Academic Journal
  15. 15
    Academic Journal

    المصدر: Siberian journal of oncology; Том 19, № 3 (2020); 156-163 ; Сибирский онкологический журнал; Том 19, № 3 (2020); 156-163 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2020-19-3

    وصف الملف: application/pdf

    Relation: https://www.siboncoj.ru/jour/article/view/1500/758; Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424. doi:10.3322/caac.21492.; McGuigan A., Kelly P., Turkington R.C., Jones C., Coleman H.G., McCain R.S. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018; 24(43): 4846–4861. doi:10.3748/wjg.v24.i43.4846.; Ferlay J., Ervik M., Lam F., Colombet M., Mery L., Piñeros M., Bray F. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer [Internet]. URL: http://gco.iarc.fr/tomorrow/graphic-isotype?type=1&population=900&mode=population&sex=0&cancer=39&age_group=value&apc_male=0&apc_female=0 (cited 23.06.2019).; Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2017 году. М., 2018. С. 86–89.; Ассоциация онкологов России. Рак поджелудочной железы. Клинические рекомендации. 2017. 35 с.; Duell E.J., Lucenteforte E., Olson S.H., Bracci P.M., Li D., Risch H.A., Fontham E.H. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol. 2012; 23(11): 2964–2970. doi:10.1093/annonc/mds140.; Huang Y., Cai X., Qiu M., Chen P., Tang H., Hu Y., Huang Y. Prediabetes and the risk of cancer: a meta-analysis. Diabetologia. 2014; 57(11): 2261–9. doi:10.1007/s00125-014-3361-2.; Wolpin B.M., Ng K., Bao Y., Kraft P., Stampfer M.J., Michaud D.S., Rifai N. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2012; 21(1): 82–91. doi:10.1158/1055-9965.EPI-11-0836.; Lynch S.M., Vrieling A., Lubin J.H., Kraft P., Mendelsohn J.B., Hartge P., Canzian F., Steplowski E., Arslan A.A., Gross M., Helzlsouer K., Jacobs E.J., LaCroix A., Petersen G., Zheng W., Albanes .D, Amundadottir L., Bingham S.A., Boffetta P., Boutron-Ruault M.C., Chanock S.J., Clipp S., Hoover R.N., Jacobs K., Johnson K.C., Kooperberg C., Luo J., Messina C., Palli D., Patel A.V., Riboli E., Shu X.O., Rodriguez Suarez L., Thomas G., Tjønneland A., Tobias G.S., Tong E., Trichopoulos D., Virtamo J., Ye W., Yu K., Zeleniuch-Jacquette A., Bueno-de-Mesquita H.B., StolzenbergSolomon R.Z. Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol. 2009; 170(4): 403–13. doi:10.1093/aje/kwp134.; Базин И.С., Соловьяненко М.А., Насырова Р.Ю., Подлужный Д., Костякова Л., Гарин А.М. Лекарственная терапия в современном лечении рака поджелудочной железы. Эффективная фармакотерапия. 2011; 24: 30–34.; Van Tienhoven G., Versteijne E., Suker M., Groothuis K.B., Busch O.R., Bonsing B.A., Zwinderman A.H. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial. J Clin Oncol. 2018; 36(18_suppl.). doi:10.1200/JCO.2018.36.18_suppl.LBA4002.; Howard T.J., Krug J.E., Yu J., Zyromski N.J., Schmidt C.M., Jacobson L.E., Madura J.A., Wiebke E.A., Lillemoe K.D. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon’s contribution to long-term survival in pancreatic cancer. J Gastrointest Surg. 2006 Dec; 10(10): 1338–45. doi:10.1016/j.gassur.2006.09.008.; Jang J.Y., Han Y., Lee H., Kim S.W., Kwon W., Lee K.H., Oh D.Y., Chie E.K., Lee J.M., Heo J.S., Park J.O., Lim D.H., Kim S.H., Park S.J., Lee W.J., Koh Y.H., Park J.S., Yoon D.S., Lee I.J., Choi S.H. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. Ann Surg. 2018 Aug; 268(2): 215–222. doi:10.1097/SLA.0000000000002705.; Reni M., Balzano G., Zanon S., Zerbi A., Rimassa L., Castoldi R., Pinelli D., Mosconi S., Doglioni C., Chiaravalli M., Pircher C., Arcidiacono P.G., Torri V., Maggiora P., Ceraulo D., Falconi M., Gianni L. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. Lancet Gastroenterol Hepatol. 2018; 3(6): 413–423. doi:10.1016/S2468-1253(18)30081-5.; Bilimoria K.Y., Talamonti M.S., Sener S.F., Bilimoria M.M., Stewart A.K., Winchester D.P., Ko C.Y., Bentrem D.J. Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg. 2008 Oct; 207(4): 510–9. doi:10.1016/j.jamcollsurg.2008.04.033.; Winter J.M., Cameron J.L., Campbell K.A., Arnold M.A., Chang D.C., Coleman J., Hodgin M.B., Sauter P.K., Hruban R.H., Riall T.S., Schulick R.D., Choti M.A., Lillemoe K.D., Yeo C.J. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg. 2006 Nov; 10(9): 1199–210. doi:10.1016/j.gassur.2006.08.018.; Zervos E.E., Rosemurgy A.S., Al-Saif O., Durkin A.J. Surgical management of early-stage pancreatic cancer. Cancer Control. 2004 JanFeb; 11(1): 23–31. doi:10.1177/107327480401100104.; Cameron J.L., Riall T.S., Coleman J., Belcher K.A. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006 Jul; 244(1): 10–5. doi:10.1097/01.sla.0000217673.04165.ea.; Talamonti M. Borderline resectable pancreatic cancer: a new classification for an old challenge. Ann Surg Oncol. 2006 Aug; 13(8): 1019–20. doi:10.1245/ASO.2006.02.902.; Varadhachary G.R., Tamm E.P., Abbruzzese J.L., Xiong H.Q., Crane C.H., Wang H., Lee J.E., Pisters P.W., Evans D.B., Wolff R.A. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006 Aug; 13(8): 1035–46. doi:10.1245/ASO.2006.08.011.; Покатаев И.А., Алиева С.Б., Гладков О.А., Загайнов В.Е., Кудашкин Н.Е., Патютко Ю.И., Трякин А.А. Практические рекомендации по лекарственному лечению рака поджелудочной железы. Злокачественные опухоли: Практические рекомендации RUSSCO. 2018; 8(3-s2): 401–413.; Neoptolemos J.P., Stocken D.D., Friess H., Bassi C., Dunn J.A., Hickey H., Beger H., Fernandez-Cruz L., Dervenis C., Lacaine F., Falconi M., Pederzoli P., Pap A., Spooner D., Kerr D.J., Büchler M.W.; European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004 Mar 18; 350(12): 1200–10. doi:10.1056/NEJMoa032295.; Crane C.H., Ben-Josef E., Small W.Jr. Chemotherapy for pancreatic cancer. N Engl J Med. 2004 Jun 24; 350(26): 2713–5.; Koshy M.C., Landry J.C., Cavanaugh S.X., Fuller C.D., Willett C.G., Abrams R.A., Hoffman J.P., Thomas C.R.Jr. A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4): 965–6. doi:10.1016/j.ijrobp.2004.11.018.; Morris S.L., Beasley M., Leslie M. Chemotherapy for pancreatic cancer. N Engl J Med. 2004; 350(26): 2713–5. doi:10.1056/NEJM200406243502617.; Oettle H., Post S., Neuhaus P., Gellert K., Langrehr J., Ridwelski K., Schramm H., Fahlke J., Zuelke C., Burkart C., Gutberlet K., Kettner E., Schmalenberg H., Weigang-Koehler K., Bechstein W.O., Niedergethmann M., Schmidt-Wolf I., Roll L., Doerken B., Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007 Jan 17; 297(3): 267–77. doi:10.1001/jama.297.3.267.; Neuhaus P., Riess H., Post S., Gellert K., Ridwelski K., Schramm H., Oettle H. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol. 2008; 26(15_suppl.): LBA4504-LBA4504.; Neoptolemos J.P., Stocken D.D., Bassi C., Ghaneh P., Cunningham D., Goldstein D., Padbury R., Moore M.J., Gallinger S., Mariette C., Wente M.N., Izbicki J.R., Friess H., Lerch M.M., Dervenis C., Oláh A., Butturini G., Doi R., Lind P.A., Smith D., Valle J.W., Palmer D.H., Buckels J.A., Thompson J., McKay C.J., Rawcliffe C.L., Büchler M.W.; European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010 Sep 8; 304(10): 1073–81. doi:10.1001/jama.2010.1275.; Neoptolemos J.P., Palmer D., Ghaneh P., Valle J.W., Cunningham D., Wadsley J., Segersvard R. ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol. 2016; 34(18suppl). doi:10.1200/JCO.2016.34.18_suppl.LBA4006.; Neoptolemos J.P., Moore M.J., Cox T.F., Valle J.W., Palmer D.H., McDonald A.C., Carter R., Tebbutt N.C., Dervenis C., Smith D., Glimelius B., Charnley R.M., Lacaine F., Scarfe A.G., Middleton M.R., Anthoney A., Ghaneh P., Halloran C.M., Lerch M.M., Oláh A., Rawcliffe C.L., Verbeke C.S., Campbell F., Büchler M.W.; European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012 Jul 11; 308(2): 147–56. doi:10.1001/jama.2012.7352.; Oettle H., Neuhaus P., Hochhaus A., Hartmann J.T., Gellert K., Ridwelski K., Niedergethmann M., Zülke C., Fahlke J., Arning M.B., Sinn M., Hinke A., Riess H. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013 Oct 9; 310(14): 1473–81. doi:10.1001/jama.2013.279201.; Conroy T., Hammel P., Hebbar M., Ben Abdelghani M., Wei A.C.C., Raoul J.L., Lecomte T. Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. J Clin Oncol. 2018; 36(18_suppl.). doi:10.1200/JCO.2018.36.18_suppl.LBA4001.; Breslin T.M., Hess K.R., Harbison D.B., Jean M.E., Cleary K.R., Dackiw A.P., Vauthey J.N. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001; 8: 123–132.; Покатаев И.А. Обзор новых исследований, способных изменить клиническую практику при раке поджелудочной железы. Злокачественные опухоли 2018; 3s1: 76–81. doi:10.18027/2224-5057-2018-8-3s1-76-81.; Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst. 1988 Jul 20; 80(10): 751–5.; Chauffert B., Mornex F., Bonnetain F., Rougier P., Mariette C., Bouché O., Bosset J.F., Aparicio T., Mineur L., Azzedine A., Hammel P., Butel J., Stremsdoerfer N., Maingon P., Bedenne L. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008 Sep; 19(9): 1592–9. doi:10.1093/annonc/mdn281.; Motoi F., Kosuge T., Ueno H., Yamaue H., Satoi S., Sho M., Honda G., Matsumoto I., Wada K., Furuse J., Matsuyama Y., Unno M.; Study Group of Preoperative Therapy for Pancreatic Cancer (Prep) and Japanese Study Group of Adjuvant Therapy for Pancreatic cancer (JSAP). Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol. 2019 Feb 1; 49(2): 190194. doi:10.1093/jjco/hyy190.; https://www.siboncoj.ru/jour/article/view/1500

  16. 16
    Academic Journal

    المصدر: Cancer Urology; Том 1, № 3 (2005); 60-65 ; Онкоурология; Том 1, № 3 (2005); 60-65 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2005-1-3

    وصف الملف: application/pdf

    Relation: https://oncourology.abvpress.ru/oncur/article/view/1204/1088; Silverberg E. Statistical and epidemiological data on urological cancer //Cancer. — 1987. — V. 60. — Р. 692—717.; Альмяшев А.З., Кулаев М.Т., Бегоулов И.В. и др. Клиника, диагностика и лечение злокачественных опухолей яичка. Методические указания для врачей и студентов. — Саранск, 2001. — 28 с.; Тюляндин С.А., Насырова Р.Ю., Стенина М.Б. и др. Гранулоцитарно-макрофагальный колониестимулирующий фактор при совместном применении с комбинированной химиотерапией карбоплатином и фосфамидом у больных диссеминированной семиномой // Вестн. ОНЦ. — 1992;2: 36—45.; Horwich A., Sleiifer D.T., Fossa S.D. et al. Randomized trial of bleomycin, etoposide and cisplatin compared with bleomycin, etoposide and carboplatin in good-prognosis metastatic non-seminomatous germ cell cancer: A multi-institutional Medical Research Council/ European Organization for Research and Treatment of Cancer trial // J. Clin. Oncol. — 1997; 15: 1844—1852.; Tjulandin S., Garin A., Stenina M. et al. Carboplatin (CBDCA), etoposide (VP-16), bleomycin (B) and GM-CSF in patients with poor-risk nonseminomatous germ cell tumors (NSGCT). — Proc. ASCO. 1993. — Аb. 776.; International Germ Cell Collaborative Group. International Germ Cell Consensus Classification: A prognostic Factor-Based Staging System for Metastatic Germ Cell Cancers // J. Clin. Oncol. — 1997; 15: 594—603.; Трякин А.А. Современные факторы прогноза при диссеминированных герминогенных опухолях у мужчин.: Дис. канд. мед. наук. — М., 2003. — 137 с.; Fossa S.D., Oliver R.T.D., Stenning S.P. et al. Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy // Eur. J. Canc. — 1997; 96: 1—8.; George D.W., Foster R.S., Hromas R.A. et al. Update on Late Relapse of Germ Cell Tumor: A Clinical and Molecular Analysis // J. Clin. Oncol. — 2003; 21, 1: 113—122.; Loehrer P.J., Lauer R., Roth B.J. et al. Salvage therapy in recurrent germ cell cancer: Ifosfamide and cisplatin plus either vinblastine or etoposide // Ann. Intern. Med. — 1988; 109: 540—546.; Rick O., Bokemeyer C., Beyer J. et al. Salvage Treatment With Paclitaxel, Ifosfamide, and Cisplatin Plus High-Dose Carboplatin, Etoposide, and Thiotepa Followed by Autologous Stem-Cell Rescue in Patients With Relapsed or Refractory Germ Cell Cancer // J. Clin. Oncol. — 2001; 1:81—88.; Тюляндин С.А. Лечение диссеминированных герминогенных опухолей у мужчин: Дис. докт. мед. наук. — М., 1993. — 182 с.; https://oncourology.abvpress.ru/oncur/article/view/1204

  17. 17
    Academic Journal
  18. 18
    Academic Journal
  19. 19
    Academic Journal

    المصدر: Abdul-Razak , H H , Rocca , C J , Howe , S J , Alonso-Ferrero , M E , Wang , J , Gabriel , R , Bartholomae , C C , Gan , C H V , Garín , M I , Roberts , A , Blundell , M P , Prakash , V , Molina-Estevez , F J , Pantoglou , J , Guenechea , G , Holmes , M C , Gregory , P D , Kinnon , C , Von Kalle , C , Schmidt , M , Bueren , J A , Thrasher ....

  20. 20
    Academic Journal